August 3, 2017 09:41 AM EDTUpdated 12:14 PM
Pharma

FDA of­fers an­oth­er speedy can­cer drug OK, ap­prov­ing Jazz’s Vyx­eos for acute myeloid leukemia

Shehla Shakoor

Managing Director

In just the lat­est case of a can­cer drug sped along by the FDA, Jazz Phar­ma­ceu­ti­cals $JAZZ to­day won ap­proval for Vyx­eos (CPX-351) as …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

A service from the Financial Times